USFDA inspects Hikal’s pharmaceutical manufacturing facility at Panoli

15 May 2023 Evaluate

The U.S. Food and Drug Administration (USFDA) has inspected Hikal’s pharmaceutical manufacturing facility located at Panoli, Gujarat. The five-day detailed preapproval inspection of an API during the period May 8, 2023-May 12, 2023 was concluded with 'Zero 483 observations’ from the USFDA Agency. This latest audit re-emphasizes the company’s commitment towards maintaining the best in class quality, compliance and regulatory standards across its manufacturing sites.

Hikal is a leading manufacturer and supplier of API's and intermediates globally.


Hikal Share Price

242.40 -10.55 (-4.17%)
05-Dec-2025 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1521.50
Zydus Lifesciences 933.10
Lupin 2089.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×